Ligation of the Fas cell surface receptor leads to activation of caspases and subsequent apoptosis. Members of the Bcl-2 family of proteins control the cellular commitment to apoptosis, although their role in Fasinduced apoptosis is ill-de®ned. In this report we demonstrate that the pro-apoptotic protein, Bax, translocates from the cytosol speci®cally to the mitochondria following Fas ligation in MCF10A1 breast epithelial cells. Bax translocation was dependent on caspase activation, and preceded the release of cytochrome c and loss of mitochondrial respiratory activity. Bax translocation occurred in concert with activation of downstream caspases as determined by cleavage of a synthetic substrate, proteolysis of poly(ADP-ribose) polymerase, and processing of procaspase-3 and -7. Overexpression of the anti-apoptotic protein, Bcl-2, prevented Bax insertion, cytochrome c release, complete processing of caspase-3 and -7, and full activation of DEVD-speci®c cleavage activity. These data establish a role for Bax mitochondrial insertion during Fas-mediated apoptosis, and support a model in which Bax insertion ampli®es the Fas apoptotic cascade through cytochrome c release and complete processing of caspases-3 and -7. In addition, our ®ndings indicate that prevention of Bax insertion into the mitochondria represents a novel mechanism by which Bcl-2 inhibits Fas-induced apoptosis.
Introduction
The Fas receptor (also known as CD95 or APO-1) is a member of the tumor necrosis factor (TNF) receptor family and is expressed in many tissue types (Nagata and Golstein, 1995) . Activation of the receptor by its ligand or a cross-linking antibody results in the induction of apoptosis (Suda et al., 1993; Trauth et al., 1989) . Loss of Fas expression or function has been demonstrated in a wide variety of human malignancies (Keane et al., 1996) , and may be a mechanism by which cells expressing mutant or viral proteins can escape elimination by the immune system, contributing to tumorigenesis.
Fas activation results in oligomerization of its intracellular death domain leading to recruitment of FADD (MORT1) which couples through its Cterminal death domain (Boldin et al., 1995; Chinnaiyan et al., 1995 Chinnaiyan et al., , 1996 . Once bound, FADD utilizes its N-terminal death eector domain (DED) to recruit procaspase-8 (FLICE/MACHa1/Mch5) to this deathinducing signaling complex (DISC) (Boldin et al., 1996; Muzio et al., 1996) . Caspase-8 is a member of a family of cysteine-dependent, aspartate-directed proteases that are involved in the initiation and execution of apoptosis (Cohen, 1997) . All caspases are synthesized as inactive proenzymes that are activated by cleavage at speci®c aspartate residues (Cohen, 1997) . Caspase-8, an`initiator' caspase, is activated at the DISC, apparently as a result of the close proximity of the caspase-8 zymogens allowing them to activate one another Muzio et al., 1998) . Although recombinant caspase-8 is able to process/ activate all known caspases directly (Cohen, 1997) , activation of downstream caspases appears to occur in a sequential, and possibly branched, cascade (Enari et al., 1996; Hirata et al., 1998) . Members of the caspase family exhibit dierent, but overlapping, substrate sequence speci®cities (Talanian et al., 1997; Cohen, 1997) . Caspase-mediated cleavage of key proteins such as poly(ADP-ribose) polymerase (PARP), nuclear lamins, gelsolin, and actin results in the characteristic apoptotic morphology and eventual dismantling of the cell (Thornberry and Lazebnik, 1998) .
Mitochondrial dysfunction occupies a central role in apoptosis invoked by various stimuli, in addition to a proposed role in amplifying the Fas-induced death signal (Adachi et al., 1997; Green and Reed, 1998; Susin et al., 1997) . Fas ligation results in the formation of mitochondrial permeability transition (PT) pores causing a loss of mitochondrial transmembrane potential and subsequent release of cytochrome c and other apoptosis inducing factors (Adachi et al., 1997; Susin et al., 1997) . Cytochrome c, complexed with Apaf-1 and dATP, facilitates activation of procaspase-9 (Apaf-3) (Li et al., 1997) . Caspase-9, in turn, activates procaspase-3 (Hakem et al., 1998; Li et al., 1997) , which may serve as a convergence point for diering apoptotic stimuli (Cohen, 1997; Rosen and Casciola-Rosen, 1997) . In addition, Fas-induced activation of caspase-8 may be responsible for the direct cleavage and activation of`eector' caspases via a mitochondrial-independent pathway (Kuwana et al., 1998) . Recently, Scadi et al. (1998) have shown that cells of dierent lineage may execute Fas-induced apoptosis by either a largely mitochondrial-independent (type I cells) or -dependent (type II cells) pathway, principally due to the amount of caspase-8 recruited to the DISC.
Regulation of apoptosis is controlled by the Bcl-2 family of proteins, which include the death agonists Bax, Bak, Bad, and Bcl-x S and antagonists Bcl-2, Bcl-x L , Bcl-w and Mcl-1 (Chao and Korsmeyer, 1998; Reed, 1997) . Bcl-2 is localized to cellular membrane compartments, including the outer mitochondrial membrane (Krajewski et al., 1993) , and overexpression of Bcl-2 or its homolog, Bcl-x L , inhibits the mitochondrial PT and cytochrome c release (Kluck et al., 1997; Susin et al., 1996; Yang et al., 1997) . Bcl-x L has been shown to interrupt proteolytic processing of caspase-7 by caspase-8 during Fas-induced apoptosis . Although Bcl-2 inhibits apoptosis induced by a variety of stimuli, there have been con¯icting reports on its ability to block Fas-induced apoptosis. The apparent dierences in the ability of Bcl-2 to inhibit Fas-induced apoptosis may re¯ect cell-lineage phenomena, and may de®ne type I versus type II cells (Scadi et al., 1998) .
Recent data indicate that Bax is a monomeric and predominantly cytosolic protein in unstressed cells despite the presence of a C-terminal hydrophobic sequence Hsu and Youle, 1998; Wolter et al., 1997) . During apoptosis induced by glucocorticoids, g-irradiation, cytokine withdrawal, and staurosporine (STP), Bax translocates to cellular membranes Youle, 1998; Wolter et al., 1997) . Using ectopic expression of a Bax-green¯uorescent protein fusion molecule, it was reported that membrane insertion was speci®c to the mitochondria . Deletion of the Cterminal domain inhibits the ability of Bax to insert into membranes and induce cell death . Enforced dimerization of Bax also results in its membrane translocation and induces cell death (Gross et al., 1998) . Furthermore, recombinant Bax has been shown to cause cytochrome c release from mitochondria both in vitro (Jurgensmeier et al., 1998) and in intact cells (Rosse et al., 1998) . Taken together, these data suggest a model in which Bax insertion into the mitochondrial membrane causes release of cytochrome c resulting in activation of caspases and cellular apoptosis. In the absence of caspase activity Bax membrane insertion may still invoke cell death due to mitochondrial dysfunction (Xiang et al., 1996) .
We have investigated the role of Bax and Bcl-2 in Fas-mediated apoptosis of breast epithelial cells. Our data demonstrate that Bax membrane translocation occurs during apoptosis induced by ligation of Fas. Translocation was speci®c to the mitochondria and preceded loss of mitochondrial respiratory function and cell membrane integrity. Insertion of Bax into the mitochondrial membrane, which was dependent on caspase activity, was strongly associated with release of cytochrome c from the mitochondria, and followed a similar timecourse as activation of DEVD-speci®c caspases. Overexpression of Bcl-2 inhibited Bax membrane insertion, cytochrome c release, complete processing of caspase-3 and -7 and apoptosis induced by Fas. These data suggest that complete processing of caspase-3 and -7 requires Bax mitochondrial membrane insertion and cytochrome c release, and identify a novel mechanism by which Bcl-2 inhibits Fas-induced apoptosis.
Results

Selection of stable MCF10A1 Bcl-2 transfectants
Ninety-two clones derived from MCF10A1 wild type (WT) transfected with pSFFV-Bcl-2 vector and 12 clones transfected with pSFFV-neo vector were screened by immunoblot analysis for Bcl-2 protein expression. All of the pSFFV-neo clones were negative for Bcl-2 expression. Figure 1 demonstrates that there is no detectable Bcl-2 expression in MCF10A1 WT or a pSFFV-neo clone (N10), compared with the high expression in the pSFFV-Bcl-2 transfectants, B30 and B84. HeLa B5, a previously described human cervical carcinoma clone transfected with the pSFFV-Bcl-2 vector, was used as a positive control (Lock and Stribinskiene, 1996) . Bcl-2 expression in clone B30 was also determined by immuno¯uorescence, which revealed homogeneous overexpression in the population (data not shown). Figure 1 also demonstrates that overexpression of Bcl-2 did not alter Bax protein expression. Additional preliminary experiments demonstrated by¯ow cytometry that all clones express equivalent amounts of Fas receptor on their surface (data not shown). Clones N10 and B30 were selected for further characterization and the results are shown below.
Overexpression of Bcl-2 inhibits Fas-induced cell death
We investigated the ability of Bcl-2 to protect against Fas-induced cell death in MCF10A1 cells. Treatment of N10 cells with anti-Fas resulted in the loss of cell membrane integrity (Figure 2a ) and mitochondrial respiration ( Figure 2b ) following a similar time course, both of which were signi®cantly delayed by Bcl-2 overexpression (B30 cells).
Bax insertion occurs following Fas ligation and is inhibited by Bcl-2
In order to determine whether Bax translocation from the cytosol to the membrane compartment occurs during Fas-mediated cell death, MCF10A1 N10 cells were treated with anti-Fas antibody and subcellular Figure 1 Immunoblots of actin, Bcl-2, and Bax protein expression in MCF10A1 clones compared to HeLa B5 clone. Protein (50 mg) from each whole cell lysate was electrophoresed and immunoblotted as described in Materials and methods. Clones transfected with pSFFV-Bcl-2, B30 and B84, show high levels of Bcl-2 expression compared to wild type (WT) or empty vector transfected clone, N10. No signi®cant dierence in Bax expression was observed in MCF10A1 clones fractions prepared following freeze/thaw lysis. STP was used as a control treatment to induce Bax insertion since it had been shown to cause Bax redistribution in HL60 cells . Figure 3a demonstrates that a 4 h STP exposure did indeed induce Bax membrane insertion in MCF10A1 cells. In untreated cells, greater than 95% of Bax was located in the cytosolic fraction (Figure 3a , lane a). In contrast, following STP treatment, greater than 80% of Bax had relocated to the membrane compartment ( Figure 3a , lane d), while the distribution of actin remained unchanged.
Ligation of the Fas receptor also led to redistribution of Bax from the cytosol to the membrane compartment ( Figure 3b , lanes a ± h). Following treatment with anti-Fas antibody, the proportion of membrane-associated Bax increased signi®cantly in N10 cells (Figure 3b , lanes e ± h). A large shift occurred between 2 and 4 h (lanes f and g), when the percentage of Bax in the membrane fraction increased from 6 ± 37%. This trend continued, and at 8 h following anti-Fas treatment, greater that 80% of Bax was in the membrane compartment (lane h). Distribution of the mitochondrial protein, cytochrome oxidase subunit VIc (COX VIc ), remained unaltered at all timepoints ( Figure 3b ). Degradation of Bax was observed at 8 h with the appearance of a 14 kDa band (lane h). This degraded form of Bax was consistently detected at late timepoints after treatment with antiFas or STP (data not shown).
Bcl-2 expression, which was not observed in N10 cells, was localized to the membrane compartment of B30 cells and did not change with treatment ( Figure  3b , lanes m ± p). In untreated B30 cells, greater than 90% of Bax was cytosolic (lane i) indicating that overexpression of Bcl-2 had not altered the subcellular location of Bax. In contrast to N10 cells, treatment with anti-Fas antibody did not result in Bax translocation to the membrane compartment in B30 cells ( Figure 3b , lanes m ± p). Thus, in addition to inhibiting loss of viability, Bcl-2 overexpression also blocked Bax translocation to the membrane compartment following ligation of Fas. 
Bax insertion is speci®c to the mitochondria and precedes the release of cytochrome c
Immuno¯uorescence techniques were utilized to determine the exact subcellular location of Bax insertion. Mitochondria were labeled by the addition of the mitochondria-speci®c dye, Mitotracker Red, the accumulation of which is dependent on an intact mitochondrial membrane potential (DC m ). Since it has been shown that ligation of Fas results in DC m collapse, mitochondrial labeling was performed prior to treatment with anti-Fas antibody. At 0 and 4 h following Fas activation, coverslips were ®xed and colabeled for mitochondria, Bax, and cytochrome c. In untreated N10 and B30 cells, Bax (green) had a diuse staining pattern (Figure 4a and c) which showed no preferential localization to the mitochondria (Figure 4b and c). Treatment with anti-Fas antibody resulted in Bax staining becoming a very distinct punctate pattern in N10 cells ( Figure 4d ) which co-localized to the mitochondria ( Figure 4e ). The percentage of N10 cells with a punctate Bax staining pattern increased with treatment time (51% in untreated cells, 28% and 450% at 4 h and 6 h respectively, data not shown). At 6 h, the majority of the cells displaying a punctate staining pattern had apoptotic morphology (nuclear We also used immuno¯uorescence to monitor the subcellular location of cytochrome c (red) in concert with Bax (green) mitochondrial translocation (Figure 4g ± j). In untreated N10 cells, cytochrome c displayed a distinct mitochondrial staining pattern (Figure 4g ) which did not co-localize with Bax ( Figure 4h ). Following anti-Fas treatment, in almost all cells that had a punctate Bax staining pattern, the staining pattern for cytochrome c had changed to a diuse, cytosolic pattern, indicating its release from the mitochondria (Figure 4i and j) . In these cells there was no co-localization of the two signals (Figure 4j ). However, certain cells had punctate Bax staining and Figure 4 Immuno¯uorescence of Bax and cytochrome c subcellular distribution during Fas-induced apoptosis of MCF10A1 cells. N10 (a, b, d, e, g ± j) and B30 (c and f) cells growing on glass coverslips were exposed to solvent control (a ± c, g, h) or 100 ng/ml anti-Fas plus 1 mg/ml cycloheximide (d ± f, i, j) for 4 h and stained for mitochondria, Bax, or cytochrome c as described in the text. Confocal microscopy revealed the subcellular distribution of Bax (green) (a ± f), either alone (a and d) or co-labeled with Mitotracker Red (b, c, e, f). Cytochrome c staining (red) (g ± j) is shown either alone (g and i) or co-labeled with Bax (green) (h and j). In b, c, e, f, h, and j co-localization of green and red¯uorescence is indicated by yellow coloration retained some of their cytochrome c mitochondrial staining pattern, and in these cells there was colocalization of the Bax and cytochrome c signals (data not shown). A diuse cytochrome c staining pattern was never detected in the absence of Bax mitochondrial translocation (Figure 4i and j, and data not shown). These data suggest that Bax insertion into the mitochondria precedes cytochrome c release and for a period of time the two are co-localized to the mitochondria. In summary, the immuno¯uorescence results clearly show that translocation of native Bax protein was speci®c to the mitochondria. Consistent with the immunoblot data, overexpression of Bcl-2 did not alter the subcellular location of Bax in untreated cells and was able to inhibit Bax relocalization during Fas-induced apoptosis. Release of cytochrome c from the mitochondria to the cytosol appeared to be subsequent to, and dependent on, Bax insertion.
Bcl-2 expression inhibits complete processing of caspase-3 and -7
Our immuno¯uorescence data support the hypothesis that Bax translocation results in the release of mitochondrial cytochrome c which facilitates the activation of caspases. We therefore investigated the processing and activation of caspases-3, -7, and -8. Processing of caspase-8 at the DISC is at the apex of the caspase cascade in apoptosis induced by Fas ligation. Procaspase-8 was observed as a doublet of approximately 55 kDa (Figure 5a) , consistent with the report that it exists as two isoforms . Figure 5a lanes a ± h demonstrates that the 55 kDa procaspase-8 was processed in both N10 and B30 cells at a similar rate following Fas activation. It has previously been demonstrated that overexpression of Bcl-x L did not aect processing of caspase-8, but did inhibit the proteolytic processing of the downstream caspase-7 . In N10 cells, caspase-7 was completely processed with ®rst the cleavage of its prodomain resulting in a 33 kDa protein, followed by cleavage to its active 17 kDa subunit (Figure 5a lanes a ± d) . Overexpression of Bcl-2 delayed the rate of disappearance of procaspase-7 (p35, Figure 5a lanes e ± h). Most notably, Bcl-2 expression inhibited cleavage of caspase-7 to the active 17 kDa form (compare lanes c and g in Figure 5a) . Surprisingly, procaspase-3 was processed with approximately equal kinetics in both N10 and B30 cells (Figure 5a ), although Bcl-2 appeared to inhibit the processing of the p20 to the p17 (active) form (compare lanes c and g in Figure 5a ). DEVD-speci®c cleavage activity was measured by cleavage of the synthetic substrate DEVD-pNA as well as by monitoring proteolysis of endogenous PARP which contains a DEVD sequence. In N10 cells cleavage of PARP to its 89 kDa fragment was complete within 2 h of treatment (Figure 5a , lanes a ± d) whereas partial cleavage occurred in B30 cells (lanes e ± h). DEVD-speci®c cleavage activity in N10 cells increased throughout treatment (Figure 5b ). The rate of cleavage at 8 h following treatment represents a greater than 70-fold increase over untreated cells. In B30 cells DEVD cleavage activity was diminished but not completely inhibited and consistently peaked at approximately 4 h following treatment and then declined (Figure 5b ). This pro®le of DEVD-pNA cleavage activity is consistent with the PARP cleavage pattern observed in Figure 5a . Thus, in addition to blocking Bax mitochondrial insertion, overexpression of Bcl-2 also prevented complete processing of caspase-3 and -7 and diminished but did not completely prevent caspase activation and PARP cleavage. Consequently, the DEVD speci®c cleavage activity in B30 cells, albeit signi®cantly attenuated, occurs in the absence of Bax insertion.
Bax insertion and cell death are dependent on caspase activity
The broad range caspase inhibitor, z-VAD-fmk was used to determine whether Bax insertion is dependent on caspase activation. Figure 6 demonstrates that pretreatment of MCF10A1 N10 cells with z-VAD-fmk inhibited DEVD-pNA cleavage activity (Figure 6a ) as well as proteolysis of PARP (Figure 6b ). In addition, z-VAD-fmk also blocked Bax membrane insertion (Figure 6c and e) and loss of viability (Figure 6d ). These data are supported by immuno¯uorescence assays which demonstrated that pre-treatment with z-VAD-fmk prevented re-localization of Bax to the mitochondria as well as cytochrome c release following anti-Fas treatment (data not shown). Therefore, an Figure 5 Caspase processing and activity in MCF10A1 N10 and B30 cells exposed to anti-Fas antibody. MCF10A1 N10 and B30 cells were exposed to 100 ng/ml anti-Fas plus 1 mg/ml cycloheximide for 0, 2, 4, and 8 h. 
Discussion
In this report we have demonstrated that endogenous Bax protein translocates from a predominantly cytosolic location, speci®cally to mitochondria of MCF10A1 breast epithelial cells during Fas-induced apoptosis. Overexpression of Bcl-2 inhibited Bax mitochondrial translocation and cell death, indicating that a novel mechanism by which Bcl-2 inhibits Fasinduced apoptosis is to prevent Bax mitochondrial membrane insertion. Bax insertion, which was associated with cytochrome c release from the mitochondria, occurred downstream of, and was dependent on, caspase activation.
Bax has been shown to cause cytochrome c release from mitochondria and caspase activation in vitro (Jurgensmeier et al., 1998 ). In addition, high level ectopic Bax expression resulted in its localization to mitochondria and cytochrome c release (Rosse et al., 1998) . Release of cytochrome c has been shown to amplify the apoptotic signal induced by caspase-8 (Kuwana et al., 1998) . In our study, Bax translocated speci®cally to the mitochondria prior to the release of cytochrome c, which supports the model in which Bax insertion contributes to ampli®cation of the Fas apoptotic cascade following activation of caspase-8.
Several reports have suggested that the primary site for Bcl-2 regulation of apoptosis is by preventing cytochrome c release from the mitochondria (Adachi et al., 1997; Kluck et al., 1997; Yang et al., 1997) . In MCF10A1 cells, Bcl-2 inhibited both Bax insertion and cytochrome c release, indicating that a possible mechanism by which Bcl-2 prevents cytochrome c release is by inhibiting Bax insertion. Bcl-2 is not able to block Fas-induced apoptosis in all cell types, particularly lymphocytes . In addition, recent reports suggest that some cells types may be able to execute apoptosis independent of mitochondrial cytochrome c release (Kuwana et al., 1998; Scadi et al., 1998) . Whether Bax insertion also occurs in these cell types during Fasinduced apoptosis may contribute to our understanding of the dierential ability of Bcl-2 to inhibit Fasinduced apoptosis.
Caspase-8 was processed equivalently in N10 and B30 cells indicating that Bcl-2 functions downstream of caspase-8 activation. Overexpression of Bcl-2 did not inhibit cleavage of pro-caspase-3 and -7, but did result in incomplete processing of the pro-enzymes to their active forms. It has been reported that Bcl-x L overexpression inhibited caspase-7 processing to its active subunit following Fas activation . However, in that report, it was unclear whether processing of the prodomain occurred. Our data indicate that cytochrome c release from mitochondria following Bax insertion ampli®es the Fas apoptotic cascade by facilitating ®nal activation of caspase-3 and -7.
Caspase-3 and -7 both exhibit DEVD-speci®c cleavage activity (Talanian et al., 1997) , which may explain the decreased DEVD-pNA cleavage activity and incomplete proteolysis of PARP observed in B30 cells compared to N10 cells following Fas activation. Caspase-8 also exhibits DEVD cleavage activity, although at less than 100-fold the rate of catalysis compared to caspase-3 . Thus, caspase-8 may be responsible for the low level of DEVD-pNA cleavage activity and incomplete PARP degradation observed in B30 cells. Others have reported that when Bcl-x L is overexpressed, ligation of Fas leads to PARP degradation in the absence of appreciable cell death (Boise and Thompson, 1997) . Cleavage of PARP protein is unlikely to lead to cell death since genetic disruption of the PARP gene is not lethal (Wang et al., 1995) . The pro®le of caspase activity in B30 cells (processing of caspase-8 and low level of DEVD-speci®c cleavage activity) is consistent with the cascade being initiated, but without subsequent ampli®cation, presumably due to the lack of cytochrome c release.
The precise mechanism by which Bax inserts into the mitochondria is presently unknown. Bax has been reported to undergo conformational changes in its N- Figure 6 Inhibition of Fas-induced (a) activation of DEVDspeci®c cleavage activity, (b) PARP cleavage, (c) Bax membrane insertion, and (d) loss of plasma membrane integrity by z-VADfmk. (a ± e) MCF10A1 N10 cells were exposed to 100 ng/ml antiFas plus 1 mg/ml cycloheximide without (7) or with (+) 4 h pretreatment with 75 mM z-VAD-fmk. Cells were harvested as described in Materials and methods. (e) Immunoblot of Bax and actin. C and M refer to cytosolic and membrane fractions, respectively. The integer above each lane refers to the treatment time. Previous experiments determined that z-VAD-fmk treatment alone did not alter Bax subcellular distribution (data not shown). Data presented are from a single experiment, which is representative of at least two separate experiments terminus during membrane insertion, and enforced dimerization of Bax induces its translocation to mitochondria (Gross et al., 1998; Hsu and Youle, 1998 ). Our studies demonstrate that Bax translocation and cell death following Fas ligation are dependent on caspase activation. It is unlikely that caspase-3 activity is necessary for Bax insertion, since we have observed Bax translocation in MCF-7 cells which lack caspase-3 (Janicke et al., 1998 and data not shown). In a Xenopus cell free system, active caspase-8 induced rapid cytochrome c release from mitochondria, which was dependent on cleavage of an unknown cytosolic substrate (Kuwana et al., 1998) . In addition, two recent reports demonstrate that cleavage of another member of the Bcl-2 family, Bid, results in its translocation to mitochondria and cytochrome c release after caspase-8 activation Luo et al., 1998) . However, it is unlikely that Bax cleavage is required for its mitochondrial insertion as we only observed cleavage of Bax molecules already relocalized to the membrane compartment, and even then at relatively late treatment timepoints (6 ± 8 h). Another attractive mechanism for the regulation of Bax translocation that is currently under investigation, is through phosphorylation. Phosphorylation has been implicated in the regulation of several members of the Bcl-2 family (Cory and . Fas ligation activates the MAP kinase pathway downstream of caspase activation, which would be consistent with our ®nding that Bax insertion is dependent on caspase activation (Toyoshima et al., 1997).
It is currently unknown how Bcl-2 blocks Bax insertion into the mitochondria. Overexpression of Bcl-2 caused no apparent redistribution of Bax in MCF10A1 cells, in agreement with a previous report , but in contrast to another (Shibasaki et al., 1997) . In unstressed cells, Bcl-2 and Bax occupy separate subcellular locations, which questions their heterodimerization as a method of regulation. Bcl-2 has been shown to interact with multiple proteins (Reed, 1997), therefore it is possible that Bcl-2 sequesters a protein that is necessary for Bax insertion into the mitochondria. Another possibility is that Bcl-2, which is located on the outer mitochondrial membrane, physically blocks the Bax insertion site. Bcl-2 is also located in the membranes of other cellular organelles including the nucleus and endoplasmic reticulum (Krajewski et al., 1993) ; thus another possibility is that Bcl-2 may control an upstream, mitochondrial-independent event necessary for Bax insertion.
In summary, Bax insertion has been demonstrated during apoptosis induced by stimuli such as STP, girradiation, and IL-3 withdrawal (Gross et al., 1998; Hsu et al., 1997; Wolter et al., 1997) . We now demonstrate that Bax translocation also occurs as part of the Fas-induced apoptotic pathway. Our results contribute to the ordering of events during Fas-induced apoptosis, by demonstrating that Bax insertion is dependent on caspase activation and precedes cytochrome c release from the mitochondria, loss of mitochondrial respiration, and loss of plasma membrane integrity. The data presented here support a model in which Bax insertion, which can be inhibited by Bcl-2 overexpression, ampli®es the Fas apoptotic cascade through cytochrome c release and ®nal processing of caspase-3 and -7. Finally, it has been shown that Bax can invoke cell death in the absence of caspase activation (Xiang et al., 1996) , and in our experiments Bax insertion has never been detected without concomitant cell death. Thus, Bax insertion into the mitochondrial membrane probably represents an irreversible commitment to cell death.
Materials and methods
Cell culture and transfections
Mid-passage MCF10A1 cells, a spontaneously immortalized non-tumorigenic human breast epithelial cell line, were obtained from the Barbara Ann Karmanos Cancer Institute. Cells were maintained as a monolayer in DMEM : F12 (1 : 1) (Gibco) supplemented with 5% horse serum (Gibco), 20 ng/ml recombinant human epidermal growth factor (Gibco), 100 ng/ml cholera toxin (Sigma), 10 mg/ml recombinant human insulin (Gibco), 0.5 mg/ml hydrocortisone (Sigma), and 100 units/ml penicillin/streptomycin (Gibco) at 378C in a humidi®ed 5% CO 2 atmosphere. Cells stably transfected with pSFFV-Bcl-2 or pSFFV-neo vector (both kindly provided by Dr SJ Korsmeyer, Washington University Medical School, St. Louis, MO, USA) were established exactly as described previously (Lock and Stribinskiene, 1996) .
Drug and Fas antibody treatments and viability assays
Concentrated stocks of staurosporine (STP) (Sigma) were stored in DMSO at 7208C, and diluted immediately prior to use. Anti-Fas monoclonal antibody (clone CH11, Upstate Biotechnology) was stored at 7208C and diluted directly into tissue culture medium. Exponentially-dividing cells were exposed continuously to 1 mM STP or 100 ng/ml anti-Fas antibody plus 1 mg/ml cycloheximide (Calbiochem). At the indicated timepoints cells were harvested and viability was estimated as the proportion of cells that excluded 0.2% trypan blue. For the indicated experiments, cells were exposed to 75 mM z-Val-Ala-Asp(OMe)-CH 2 F (z-VAD-fmk) (Peptide Institute Inc., Osaka, Japan) for 4 h prior to the addition of anti-Fas antibody. In addition, cytotoxicity of anti-Fas antibody was determined as a measurement of mitochondrial respiratory function using the Alamar Blue TM reagent (Astral Scienti®c). For this assay, cells were seeded into 96-well tissue culture plates at a concentration of 8000 cells per well in 200 ml of media and allowed to grow for two days. Previous experiments had determined that under these conditions, MCF10A1 cells are in log phase growth. Media was removed and replaced with 200 ml of fresh media alone or fresh media containing 100 ng/ml anti-Fas with 1 mg/ml cycloheximide. At the indicated timepoints, 20 ml of Alamar Blue reagent was added to each well, mixed, and incubated at 378C for 3 h. The plates were then read on a Bio-Rad Microplate Reader and the absorbance of each well at 595 nm was subtracted from the absorbance reading at 570 nm. The results for each experiment represent the average of readings from at least six wells and each experiment was performed in triplicate. Data are represented as the average+s.e.mean of at least three separate experiments and expressed as a percentage of solvent-treated controls.
Subcellular fractionation
For separation of subcellular cytosolic and nuclear/membrane fractions, 10 7 cells were washed twice with cold PBS and resuspended in 1 ml of extraction buer (50 mM PIPES pH 7.0, 50 mM KCl, 5 mM MgCl 2 , 5 mM EGTA, 1 mM phenylmethylsulfonyl¯uoride, 10 mg/ml leupeptin, 10 mg/ml pepstatin A). Cells were lysed by 5 cycles of freezing in liquid nitrogen and thawing at 378C. After microscopic examination with trypan blue veri®ed that 495% cells were lysed, the crude lysate was centrifuged at 100 000 g for 1 h at 48C. The resultant supernatant, which consisted of the cytosol, was separated from the pellet that contained the cellular membrane and organelles, and the pellet was resuspended in 1 ml of extraction buer. Immunoblotting for the nuclear protein topoisomerase I (clone C-21, kindly provided by Dr Y-C Cheng, Yale University School of Medicine, New Haven, CT, USA) and the mitochondrial protein cytochrome oxidase subunit VIc (clone 3G5-F7-G3, Molecular Probes) revealed no cross contamination of these organelles in the cytosolic fraction by this method of fractionation. Lactate dehydrogenase activity was measured as a cytosolic marker, and experiments were only deemed valid if 495% of the total lactate dehydrogenase activity was detected in the cytosolic fraction.
Immunoblotting
Whole cell extracts were prepared by lysing 10 7 cells in 1 ml of lysis buer (50 mM Tris pH 7.4, 150 mM NaCl, 0.2% NP-40, 50 mM NaF, 5 mM EDTA, 0.1 mM orthovanadate, plus protease inhibitor cocktail (Sigma)) on ice for 30 min. The crude lysate was then centrifuged at 10 000 g for 10 min at 48C and the supernatant removed and stored at 7808C for subsequent analysis. Protein concentration was estimated by the bicinchoninic acid assay method (Pierce) using a BSA standard. Equal amounts of protein, or equal volumes of cytosol and membrane fractions, were separated by SDS polyacrylamide gel electrophoresis and transferred to polyvinylidene di¯uoride membrane. Primary antibodies used were rabbit polyclonal antisera raised against human Bcl-2, Bax, caspase-3 (PharMingen) and actin (Sigma); and mouse monoclonal antibodies against caspase-7, and -8, (PharMingen), bovine PARP (clone C-2-10, Anity Bioreagents), and cytochrome oxidase subunit VIc (Molecular Probes). Secondary antibodies used were horseradish peroxidase conjugates of donkey anti-rabbit Ig and sheep antimouse Ig (Amersham). Chemiluminescent signals were generated by the addition of SuperSignal Ultra Chemiluminescent Substrate (Pierce) and detected both on radiographic ®lm and quanti®ed by phosphoimage analysis (Bio-Rad). PARP degradation was expressed as the percentage of the 113 kDa protein proteolyzed to the 89 kDa fragment.
Caspase activity assays
Cytosolic lysates were used to estimate caspase activity by cleaving the synthetic caspase-3 substrate, N-acetyl-Asp-GluVal-Asp-p-nitroanilide (Ac-DEVD-pNA) (BIOMOL Research Laboratories). An aliquot of lysate equivalent to 100 mg of protein was added to 150 ml of reaction buer (20 mM PIPES pH 7.2, 100 mM NaCl, 1 mM EDTA, 10% sucrose, 0.1% 3-([3-cholamidopropyl]dimethylyammonio)-1-propanesulfonic acid (CHAPS), 20 mM 2-mercaptoethanol) containing the peptide substrate (®nal concentration 100 mM) in a 96-well plate. The absorbance of each well at 405 nm (A405) was read both before and following a 1 h incubation at 378C. Ac-DEVD-pNA cleavage activity was expressed as A405 h 71 mg protein
71
. Preliminary experiments had veri®ed linearity of response over time and protein concentration (data not shown).
Immuno¯uorescence and confocal microscopy
Cells were grown on No 1 glass coverslips under the same conditions described above. Prior to drug treatment, cells were labeled with Mitotracker Red CM-H 2 XRos (Molecular Probes) for 45 min at 378C. Drug treatments were carried out as described above. At the indicated timepoints, cells were washed twice in PBS, ®xed for 30 min in 3% formaldehyde and permeabilized for 2 min with 0.2% Triton X-100. Nonspeci®c binding was blocked by incubation with 5% bovine serum albumin (BSA) in PBS for 1 h. Cells were then incubated with rabbit anti-Bax polyclonal antibody 06-499 (Upstate Biotechnology) and mouse monoclonal anticytochrome c 6H2.B4 (PharMingen) diluted 1 : 50 in 3% BSA/PBS for 1 h at 378C in a humidi®ed chamber. Excess antibody was removed by washing the coverslips four times with PBS. Cells were then incubated with the secondary antibodies, FluoroLink Cy2 labeled goat anti-rabbit IgG and FluoroLink Cy3 labeled goat anti-mouse IgG (Amersham), diluted 1 : 1000 in 3% BSA/PBS, for 1 h protected from light. After washing four times with PBS, coverslips were mounted onto microscope slides using ProLong Antifade mounting reagent (Molecular Probes). Control slides were stained with non-speci®c rabbit IgG (Sigma) and both secondary antibodies. Cells were viewed under a Zeiss Axioskop 20 uorescence microscope and imaged using the Bio-Rad MRC 1024 Laser Scanning Confocal Imaging System. For each timepoint, 1000 cells were scored as having a punctate or diuse Bax staining pattern. The numbers reported represent an average of two experiments.
